SLC34A2: A Protein Targeted for Cancer, Neurodegenerative diseases, and Cardiovascular diseases

Target Name: SLC34A2

NCBI ID: G10568

SLC34A2

SLC34A2: A Protein Targeted for Cancer, Neurodegenerative diseases, and Cardiovascular diseases

SLC34A2 (NPT2B_HUMAN) is a protein that is expressed in various tissues of the human body, including the brain, heart, and kidneys. It is a member of the NPT2 gene family, which encodes a protein involved in the intracellular signaling pathway known as phospholipids Inositol acyl (PIP2).

The PIP2 signaling pathway is a critical pathway involved in many cellular processes, including cell signaling, migration, and invasion. The protein encoded by the NPT2 gene is a key regulator of this pathway, and is involved in the formation of IP2, a crucial signaling molecule that can modulate various cellular processes.

SLC34A2 has been identified as a potential drug target or biomarker for several diseases, including cancer, neurodegenerative diseases, and cardiovascular diseases.

In cancer, SLC34A2 has been shown to be involved in the development and progression of various types of cancer, including breast, ovarian, and colorectal cancers. Studies have shown that inhibiting SLC34A2 activity can inhibit the growth and survival of cancer cells, and may be an effective strategy for cancer treatment.

In neurodegenerative diseases, SLC34A2 has been implicated in the development and progression of conditions such as Alzheimer's disease and Parkinson's disease. Studies have shown that SLC34A2 is involved in the formation of neurofibrillary tangles and neuroglial cells, which are thought to contribute to the progression of these conditions.

In cardiovascular diseases, SLC34A2 has been shown to be involved in the development and progression of various cardiovascular conditions, including hypertension, heart failure, and myocardial infarction. Studies have shown that SLC34A2 is involved in the regulation of cellular signaling pathways that are important for cardiovascular function, and that inhibiting SLC34A2 activity may be an effective strategy for treating cardiovascular diseases.

In conclusion, SLC34A2 is a protein that is involved in a critical signaling pathway that is involved in many cellular processes in the human body. Its potential as a drug target or biomarker makes it an attractive target for the development of new therapies for a variety of diseases. Further research is needed to fully understand the role of SLC34A2 in disease and to develop effective treatments.

Protein Name: Solute Carrier Family 34 Member 2

Functions: Involved in actively transporting phosphate into cells via Na(+) cotransport

The "SLC34A2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SLC34A2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets